LN Robotics
Founded in 2019, LN Robotics Inc. was established in collaboration with the medical staff of Asan Medical Center with the aim of commercializing medical robots to address the unmet needs of clinical sites. Our main focus has been redefining cardiovascular intervention through advanced robotics incorporating innovative technologies such as haptics, artificial intelligence, big data, and biotechnology, with significant input from clinical experts. We possess optimized capabilities for product design, development, evaluation, pre-clinical trials, and clinical trials through joint research with clinical medical staff.
Advanced Vascular Intervention Assistive Robot
Our first medical robot, named AVIAR (Advanced Vascular Intervention Assistive Robot), is designed to help treat patients with vascular diseases. The current focus is on PCI (Percutaneous Coronary Intervention) to treat cardiovascular diseases, which are one of the leading causes of death worldwide. We pursue beyond the limits of conventional manual techniques to improve the implementation of robotic intervention procedures. The key benefits of AVIAR are to reduce radiation for clinicians and patients and to minimize inter-operator variance in the procedure.
In 2023, we obtained Korea’s first approval for a cardiovascular interventional procedure robot. We aim to install and sell it in hospitals in Korea by the first half of 2025 and to obtain FDA approval by 2026 and CE approval by 2027.
- For more information, visit: https://lnrobo.com
